Skip to main content

Nanogen Licenses Probe Technology to Quest

NEW YORK (GenomeWeb News) – Nanogen has licensed its minor groove binder probe technology to Quest Diagnostics for use in human in vitro diagnostics tests.

Clinical lab firm Quest will pay Nanogen an undisclosed upfront fee and royalties based on sales of products that incorporate the MGB Probe technology.

Nanogen noted that licensing deals for the MGB Probe technology now represents the majority of Nanogen's revenues. It said that it has more than 40 reagent and kit products sold for IVD use usnder the MGB Alert and Q-PCR Alert brands.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.